Mitsubishi UFJ Kokusai Asset Management Co. Ltd. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 209,536 shares of the biopharmaceutical company’s stock after selling 27,191 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $14,831,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% during the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 11 shares during the last quarter. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 32 shares during the last quarter. First Heartland Consultants Inc. lifted its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after acquiring an additional 39 shares during the last quarter. Arrow Financial Corp lifted its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 45 shares during the last quarter. Finally, Westover Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 46 shares during the last quarter. 73.98% of the stock is owned by institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 82.57 on Thursday. The company has a market cap of $107.83 billion, a P/E ratio of 8.97 and a beta of 1.14. The stock has a 50 day moving average of $81.81 and a 200 day moving average of $72.01. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the firm earned $3.08 EPS. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/10/12/gilead-sciences-inc-gild-shares-sold-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last ninety days, insiders sold 486,819 shares of company stock worth $39,298,919. Insiders own 1.30% of the company’s stock.
A number of analysts have recently issued reports on GILD shares. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price objective on shares of Gilead Sciences in a report on Thursday, August 31st. Credit Suisse Group reaffirmed an “outperform” rating and set a $85.00 price objective (up from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target for the company in a research note on Monday, June 26th. Twelve analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.86.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.